Public Appeal Process Completed – Facility
Construction to Begin in May
2019
TSX | NYSE: ACB
EDMONTON, April 18, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) confirmed today
that, further to its press release dated April 5, 2019, the public appeal process related
to the German cannabis production tender has been completed, and
Aurora's contract with the German Federal Institute for Drugs
and Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte BfArM) has now been finalized.
The approval will allow Aurora to begin construction of a new,
state-of-the art, indoor cannabis production facility in Leuna,
Germany in May 2019 and the Company anticipates completion
within 12 months of ground breaking. Initial shipments of locally
grown cannabis are expected to become available to German medical
patients starting in October 2020,
with the new facility producing a minimum of 4,000 kg over a
four-year period, to be expanded over time as regulations
permit.
"We are thrilled with the positive outcome of the tender
process, and excited to start construction on our latest production
facility," said Neil Belot, Chief
Global Business Development Officer. "We are very proud of the work
done by our European team. In addition to providing German
medical patients with a local supply of high-quality, medical grade
cannabis, this new facility will also bring additional new jobs to
the German labour market. It's a strong validation of our
production and distribution standards to have been recognized as
having the highest-rated overall concept out of 79 tender
applications, and we look forward to continuing to increase
availability of medical cannabis in this important market."
"Our successful proposal was focused on implementing the Aurora
standard, pharmaceutical grade, cultivation techniques, while
leveraging the broad competences of our team of architects,
engineers, pharmacists, plant specialists and project management
professionals," said Dr. Axel Gille,
Managing Director of Aurora Europe.
"Construction of this new facility in Leuna is the next logical
step in expanding our Europe-wide production network to ensure
medical patients have safe access to consistent, high-quality
medicinal cannabis flowers and full extracts."
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
and ICC Labs – Aurora is distinguished by its reputation as a
partner and employer of choice in the global cannabis sector,
having invested in and established strategic partnerships with a
range of leading innovators, including: Radient Technologies Inc.
(TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group
Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE:HITI).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Neither the TSX, NYSE nor their Regulation Services Provider
(as that term is defined in the policies of the TSX and NYSE)
accepts responsibility for the adequacy or accuracy of this
release.
Terry Booth, CEO
Aurora Cannabis Inc.
Forward-Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"), including, but not
limited to, statements with respect to the performance of the
Company. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur, and include, but are
not limited to statements regarding the construction and completion
of the Company's production facility in Germany, and
the production capacity of the facility. These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-provides-update-on-german-cannabis-production-tender-300834379.html
SOURCE Aurora Cannabis Inc.